254 related articles for article (PubMed ID: 15025747)
1. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
2. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
4. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
5. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
7. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
8. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
9. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
10. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
[TBL] [Abstract][Full Text] [Related]
11. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
12. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Jan MW; ZumBrunnen TL; Kazmi YR; VanDenBerg CM; Desai HD; Weidler DJ; Flockhart DA
Drug Metabol Drug Interact; 2002; 19(1):1-11. PubMed ID: 12222750
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
[TBL] [Abstract][Full Text] [Related]
17. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
19. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Br J Clin Pharmacol; 2008 May; 65(5):767-74. PubMed ID: 18294333
[TBL] [Abstract][Full Text] [Related]
20. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
